Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.

Priya VartMuthiah VaduganathanNiels JongsGiuseppe RemuzziDavid C WheelerFan Fan Hou Finnian R Mc Causland Glenn M Chertow Hiddo J Lambers Heerspink

Published in: Clinical journal of the American Society of Nephrology : CJASN (2022)

Benazepril for Advanced Chronic Renal Insufficiency, NCT00270426, and a Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (Dapa-CKD), NCT03036150.

Keyphrases

chronic kidney disease
type diabetes
cardiovascular disease
cardiovascular events
risk factors
stem cells
metabolic syndrome
skeletal muscle
insulin resistance
smoking cessation